# US 5,352,585 A · System for benzodiazepine detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,352,585 A
- Document ID: US5352585A
- Status: Granted
- Kind: A
- Application number: 08/084,845
- Filed: 1993-06-29
- Granted: 1994-10-04
- Earliest claimed: 1993-06-29
- Assignees: Bio-Rad Laboratories, Inc.
- Inventors: Steven R. Binder; David L. King
- Web page: https://patentgrep.com/patent/US5352585A

## CPC

- G01N 30/461: {with serial coupling of separation columns}
- G01N 30/88: Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N 30/02: Column chromatography
- G01N 30/06: Preparation
- G01N 30/14: by elimination of some components
- G01N 30/34: of fluid composition, e.g. gradient (G01N30/36 takes precedence)
- G01N 30/468: {involving switching between different column configurations}
- G01N 30/74: Optical detectors {(measurement of intensity, velocity, spectral content, polarisation, or phase of infrared, visible or ultraviolet light G01J)}
- G01N 30/8606: {Integration}
- G01N 30/8679: {Target compound analysis, i.e. whereby a limited number of peaks is analysed}
- G01N 2030/027: {Liquid chromatography}
- G01N 2030/085: {using absorbing precolumn}
- G01N 2030/8804: {automated systems}
- G01N 2030/8813: {biological materials}
- G01N 2030/8831: {involving peptides or proteins}
- Y10S 436/901: Drugs of abuse, e.g. narcotics, amphetamine
- Y10T 436/14: Heterocyclic carbon compound [i.e. , O, S, N, Se, Te, as only ring hetero atom]
- Y10T 436/145555: Hetero-N
- Y10T 436/17: Nitrogen containing
- Y10T 436/25: including sample preparation
- Y10T 436/25125: Digestion or removing interfering materials
- Y10T 436/255: including use of a solid sorbent, semipermeable membrane, or liquid extraction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Biological samples are analyzed for benzodiazepines in a single isocratic analysis using a chromatographic column system containing an immobilized enzyme reactor which cleaves glucuronic acid-conjugated benzodiazepines, an anion exchange column, a hydrophobic cation exchange column and a reverse-phase analytical column. Preferred methods of performing the analysis further involve the use of a hydrophobic cation exchange precolumn prior to the anion exchange column. The system readily lends itself to automation, automatic periodic sampling and benzodiazepine identification and quantification. The system is particularly well adapted to the determination and identification of benzodiazepines in urine samples.

## Claims

### Claim 1

A method for analyzing a biological sample for the presence of benzodiazepines, said method comprising:
(a) passing said sample through the following media in the sequence indicated:
(i) a contact medium comprised of an immobilized glucuronosohydrolase to cleave glucuronic acid from any species conjugated with said glucuronic acid;
(ii) a first separation medium comprised of an anion exchange medium, under conditions permitting retention of hydrophobic anions, with substantially no retention of benzodiazepines;
(iii) a second separation medium comprised of a hydrophobic cation exchange medium under conditions permitting retention of basic compounds of stronger basicity than benzodiazepines, with substantially no retention of benzodiazepines; and
(iv) a third separation medium comprised of a reverse-phase medium, under conditions permitting the chromatographic separation of benzodiazepines; and
(b) detecting said benzodiazepines individually upon their emergence from said third separation medium.

### Claim 2 (depends on 1)

A method in accordance with claim 1 in which said sample is passed through said first, second and third separation media by a carrier liquid comprised of an aqueous solution of a member selected from the group consisting of methanol, ethanol and isopropanol, at a concentration of from about 10% to about 50% by weight and at an approximately neutral pH.

### Claim 3 (depends on 1)

A method in accordance with claim 1 in which said sample is passed through said first, second and third separation media by a carrier liquid comprised of an aqueous solution of a member selected from the group consisting of methanol, ethanol and isopropanol, at a concentration of from about 30% to about 50% by weight and at an approximately neutral pH.

### Claim 4 (depends on 1)

A method in accordance with claim 1 in which said sample is passed through said first, second and third separation media by a carrier liquid comprised of an aqueous solution of ethanol at a concentration of from about 30% to about 50% by weight and at an approximately neutral pH.

### Claim 5 (depends on 1)

A method in accordance with claim 1 further comprising passing said sample through a preliminary separation medium prior to passing said sample through said first separation medium, said preliminary separation medium comprised of a hydrophobic cation exchange medium of a hydrophobicity sufficiently stronger than said second separation medium to retain any benzodiazepines in said sample, said sample being passed through said preliminary separation medium under conditions permitting retention by said preliminary separation medium of said benzodiazepines to the exclusion of a preliminary group of interfering species comprised of inorganic salts, proteins, peptides and hydrophilic compounds in said sample, then eluting said retained sample components free of said preliminary group of interfering species and thereby eliminating said interfering species from said sample prior to passage of said sample through said first separation medium.

### Claim 6 (depends on 5)

A method in accordance with claim 5 in which said passage of said sample through said preliminary separation medium is performed subsequent to said passage of said sample through said contact medium.

### Claim 7 (depends on 5)

A method in accordance with claim 5 in which said passage of said sample through said preliminary separation medium is comprised of:
(1) applying said sample to said preliminary separation medium with an application buffer comprised of a low ionic strength aqueous buffer at a pH of from about 5 to about 7;
(2) purging said preliminary separation medium with an aqueous alkaline buffer to remove therefrom acidic drugs present in said sample;
(3) purging said preliminary separation medium with an aqueous acidic buffer to increase interactions between basic compounds and said preliminary separation medium, thereby enhancing the ease of separation of basic compounds present in said sample from each other according to their degree of basicity; and
(4) eluting benzodiazepines from said preliminary separation medium preferentially relative to interfering compounds which are more basic than benzodiazepines by use of a carrier liquid comprised of an aqueous solution of a member selected from the group consisting of methanol, ethanol and isopropanol, at a concentration of from about 10% to about 50% by weight and at an approximately neutral pH.

### Claim 8 (depends on 7)

A method in accordance with claim 7 in which:
said aqueous alkaline buffer of step (2) is comprised of a buffer at a pH of from about 10 to about 12, containing from about 1% to about 10% by weight of a member selected from the group consisting of methanol, ethanol and isopropanol;
said aqueous acidic buffer of step (3) is comprised of a buffer at a pH of from about 4 to about 5.5; and
said carrier liquid of step (4) is comprised of an aqueous solution of a member selected from the group consisting of methanol, ethanol and isopropanol at a concentration of from about 30% to about 50% by weight.

### Claim 9 (depends on 7)

A method in accordance with claim 7 in which said preliminary separation medium is a polymeric medium with sulfonic acid functional sites.

### Claim 10 (depends on 7)

A method in accordance with claim 7 in which said preliminary separation medium is a sulfonated styrene gel.

### Claim 11 (depends on 1)

A method in accordance with claim 1 in which said immobilized glucuronosohydrolyase of step (a)(i) is .beta.-D-glucuronide glucuronosohydrolase immobilized on an agarose gel.

### Claim 12 (depends on 1)

A method in accordance with claim 1 in which said first separation medium is a polymeric medium with quaternary ammonium functional sites.

### Claim 13 (depends on 1)

A method in accordance with claim 1 in which said first separation medium is a styrene-divinylbenzene resin with tetramethylammonium functional sites.

### Claim 14 (depends on 1)

A method in accordance with claim 1 in which said second separation medium is a derivatized silica bearing sulfonic acid functional sites.

### Claim 15 (depends on 1)

A method in accordance with claim 1 in which said second separation medium is a derivatized silica beating propyl-sulfonic acid functional sites.

### Claim 16 (depends on 1)

A method in accordance with claim 1 in which said third separation medium is a derivatized silica bearing alkyl functional sites.

### Claim 17 (depends on 1)

A method in accordance with claim 1 in which said third separation medium is a dimethyl alkyl silane bonded to silica, in which said alkyl group contains at least 6 carbon atoms.

### Claim 18 (depends on 1)

A method in accordance with claim 1 in which said third separation medium is dimethyloctadecylsilane bonded to silica.

### Claim 19

A method for analyzing a biological sample for the presence of benzodiazepines, said method comprising:
(a) passing said sample through the following media in the sequence indicated:
(i) a contact medium comprised of .beta.-D-glucuronide glucuronosohydrolase immobilized on an agarose gel, to cleave glucuronic acid from any species present in said sample which is conjugated with said glucuronic acid;
(ii) a sulfonated styrene gel, under conditions permitting retention thereby of sample components comprised of any benzodiazepines present in said sample to the exclusion of a preliminary group of interfering species comprised of substantially all inorganic salts, proteins, peptides and hydrophilic compounds in said sample, thereby eliminating said interfering species from said sample prior to passage of said sample through said first separation medium;
(iii) a styrene-divinylbenzene resin with tetramethylammonium functional sites, under conditions permitting retention of hydrophobic anions, with substantially no retention of benzodiazepines;
(iv) a derivatized silica bearing propyl-sulfonic acid functional sites, under conditions permitting retention of basic compounds of stronger basicity than benzodiazepines, with substantially no retention of benzodiazepines; and
(v) a reverse-phase medium comprised of dimethyloctadecylsilane bonded to silica, under conditions permitting the chromatographic separation of benzodiazepines;
steps (a)(iii), (a)(iv) and (a)(v) being performed by way of a carrier liquid comprised of an aqueous solution of a member selected from the group consisting of methanol, ethanol and isopropanol, at a concentration of from about 30% to about 50% by weight and at an approximately neutral pH; and
(b) detecting said benzodiazepines individually their emergence from said third separation medium.